Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma

NCT03359018 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Progression-free Survival
Overall Survival
Clinical Benefit Rate
Toxicity

Interventions

DRUG: Apatinib
DRUG: SHR-1210

Sponsor

Peking University People's Hospital

Collaborators

[object Object]